In yesterday’s Wall Street session, Sanofi (NASDAQ:SNY) shares traded at $46.92, down -2.13% from the previous session.
As of this writing, 20 analysts cover Sanofi (NASDAQ:SNY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $68.27 and a low of $44.02, we find $55.08. Given the previous closing price of $47.94, this indicates a potential upside of 14.89 percent. SNY stock price is now 10.74% away from the 50-day moving average and -1.36% away from the 200-day moving average. The market capitalization of the company currently stands at $120.22B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 7 analysts who have given it a hold rating, whereas 10 have given it a buy rating. Brokers who have rated the stock have averaged $54.34 as their price target over the next twelve months.
, while ‘SVB Leerink’ rates the stock as ‘Outperform’.
A total of 16.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SNY stock. A new stake in Sanofi shares was purchased by IRON TRIANGLE PARTNERS LP during the first quarter worth $42,228,000. KYNAM CAPITAL MANAGEMENT, LP invested $28,152,000 in shares of SNY during the first quarter. In the first quarter, SIO CAPITAL MANAGEMENT, LLC acquired a new stake in Sanofi valued at approximately $16,745,000. BALYASNY ASSET MANAGEMENT LLC acquired a new stake in SNY for approximately $14,260,000. AFFINITY ASSET ADVISORS, LLC purchased a new stake in SNY valued at around $14,076,000 in the second quarter. In total, there are 751 active investors with 10.30% ownership of the company’s stock.
Thursday morning saw Sanofi (NASDAQ: SNY) opened at $46.86. During the past 12 months, Sanofi has had a low of $36.91 and a high of $57.79. As of last week, the company has a debt-to-equity ratio of 0.30, a current ratio of 1.30, and a quick ratio of 0.90. The fifty day moving average price for SNY is $42.54 and a two-hundred day moving average price translates $47.63 for the stock.
The latest earnings results from Sanofi (NASDAQ: SNY) was released for Jun, 2022. The net profit margin was 16.40% and return on equity was 10.90% for SNY. For the current quarter, analysts expect SNY to generate $11.5B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/27/2022. Investors who held shares on 05/27/2022 were paid a $0.2971788 dividend. On an annualized basis, this represents a $1.75 dividend and a 3.72% percent yield. There was an ex-dividend date of 05/26/2022 for this dividend.
Sanofi(SNY) Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
